PF-04634817

**PF‑04634817** is an investigational small molecule developed by Pfizer as a dual antagonist of the chemokine receptors CCR2 and CCR5. These receptors are involved in the recruitment of leukocytes to sites of inflammation and tissue injury. The drug was designed for oral administration and was evaluated primarily for diabetic nephropathy (DN) and diabetic macular edema (DME). In clinical trials, it showed modest efficacy in reducing albuminuria in type 2 diabetes patients with nephropathy already on angiotensin receptor blocker therapy, as well as a modest improvement in best-corrected visual acuity in DME patients—though it was inferior to intravitreal ranibizumab for this indication. Due to limited efficacy despite a tolerable safety profile, further development was discontinued[1][5][6].

Other names

1228111-63-4UNII-51M3FB9B9EUNII51M3FB9B9EUNII 51M3FB9B9E[(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1S,4S)-5-[6-(trifluoromethyl)pyrimidin-4 yl]-2,5-diazabicyclo[2.2.1]heptan 2 yl]methanone